Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus
about
Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutantsStable replication of the EBNA1/OriP-mediated baculovirus vector and its application to anti-HCV gene therapyIn vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracilPhenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitroResistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.Agents in clinical development for the treatment of chronic hepatitis B.The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitroReview article: Nucleoside analogues for the treatment of chronic hepatitis B.Baculovirus as a highly efficient expression vector in insect and mammalian cells.Mutations affecting the replication capacity of the hepatitis B virus.Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.Molecular methods in the diagnosis and management of chronic hepatitis B.Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus.The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.Understanding the molecular basis of HBV drug resistance by molecular modeling.Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma.Treatment of recurrent hepatitis B infection in liver transplant recipients.Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype.Human foreskin fibroblast-like stromal cells can differentiate into functional hepatocytic cells.Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.
P2860
Q24563991-E02C4F4C-3125-411C-AA78-886C024F0A5CQ27490200-9C43BFCB-BB6B-4075-8302-8722C8284EBAQ28345952-BBF72809-F92B-40CB-8F45-CE114E605D9AQ34112556-C96CC679-ED1E-415A-9DC6-7C6FDF7C66DFQ34299035-B3BC5256-B083-4471-B75C-5413C2953CFBQ35014297-B3676BE4-44EB-4617-98CE-26F66367D7DEQ35185749-4C1616B4-96C9-4483-9CA4-81C57DB7E6DCQ35879053-BE1713CB-66F9-48B3-BD46-95226F3047ECQ35987869-0344DAB2-71F9-4814-9D2E-1E523987A607Q36075878-B4DFDE2E-C6D9-44F6-8DA3-F974221FD2E9Q36515349-D0BB69E7-8656-4B7E-9BB4-DDBCB3B34D0DQ37074608-6FE6AD43-1EB0-4EC4-863F-7E2CD216F889Q37544769-E551B4BB-82FF-459C-BEAF-9A1894B3A0BBQ37801940-2E9B7513-4D46-47B9-B7DE-1C93F58FA746Q38071400-6C7171DE-4070-496D-A5AF-A6003F483351Q39652624-289F77F7-375A-431D-86AE-0A0FCD44FD77Q39652664-54790B07-A628-44DA-98D9-DEB923F5E4A6Q40012022-9FE2965E-AF47-4B26-A8CE-906BCDE5E671Q40052006-92D557D5-1D8A-407B-9657-E8A5A28C7CE3Q40164099-BE573A5F-9A7C-4494-BF4F-916C0ABC3416Q40262602-B8FE651F-3879-4F25-9A92-A9474AFB69E7Q40276594-66EACCFC-2330-4697-ABA7-6D76FACC9C6BQ40629253-DCCD73B2-C4DB-45DC-AD97-E763BFCBC474Q40707320-5A8CD05C-56F1-4B11-A163-8C60BBC9EDADQ42275873-3DF3C71B-3EEE-4832-A39F-4CB10E8D576BQ45227673-8C80173D-6902-48FB-AF30-0D9BB532D9FF
P2860
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Cross-resistance testing of an ...... t strains of hepatitis B virus
@ast
Cross-resistance testing of an ...... t strains of hepatitis B virus
@en
Cross-resistance testing of an ...... t strains of hepatitis B virus
@nl
type
label
Cross-resistance testing of an ...... t strains of hepatitis B virus
@ast
Cross-resistance testing of an ...... t strains of hepatitis B virus
@en
Cross-resistance testing of an ...... t strains of hepatitis B virus
@nl
prefLabel
Cross-resistance testing of an ...... t strains of hepatitis B virus
@ast
Cross-resistance testing of an ...... t strains of hepatitis B virus
@en
Cross-resistance testing of an ...... t strains of hepatitis B virus
@nl
P2093
P2860
P1476
Cross-resistance testing of an ...... t strains of hepatitis B virus
@en
P2093
C Trautwein
D Colledge
S Locarnini
T G Miller
P2860
P304
P356
10.1128/AAC.45.6.1705-1713.2001
P407
P577
2001-06-01T00:00:00Z